Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
KalVista Pharmaceuticals, Inc. (KALV)
|
Add to portfolio |
|
|
|
| Price: |
$26.15
| | Metrics |
| OS: |
34.2
|
M
| |
-57
|
% ROE
|
| Market cap: |
$895
|
M
| |
-90
|
% ROIC
|
|
Net cash:
|
$149
|
M
| |
$4.36
|
per share
|
|
EV:
|
$746
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($102)
|
M
| |
|
|
|
EBIT
|
($103)
|
M
| |
|
|
| EPS |
($3.33)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Apr-30-23 | Apr-05-23 | Apr-30-22 | Apr-05-22 | Apr-30-21 | Apr-30-20 | Apr-30-19 | Apr-30-18 |
| Revenues | 0.0 | 80.3 | 0.0 | 70.2 | 0.0 | 12.7 | 16.1 | 8.4 |
| Revenue growth | | 14.4% | | | -100.0% | -21.3% | 92.1% | 458.1% |
| Cost of goods sold | 0.0 | 160.6 | 0.0 | 140.3 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | -80.3 | 0.0 | -70.2 | 0.0 | 12.7 | 16.1 | 8.4 |
| Gross margin | | -100.0% | | -100.0% | | 100.0% | 100.0% | 100.0% |
| Research and development | 80.3 | | 70.2 | | 41.3 | 40.2 | 35.0 | 18.2 |
| General and administrative | 30.6 | 30.6 | 26.4 | 26.4 | 16.6 | 13.0 | 10.9 | 8.9 |
| EBIT | -110.9 | -110.9 | -96.6 | -96.6 | -57.9 | -40.5 | -29.8 | -18.7 |
| EBIT margin | | -138.1% | | -137.7% | | -319.4% | -184.9% | -222.8% |
| Pre-tax income | -92.9 | -92.9 | -82.3 | -82.3 | -46.2 | -29.2 | -20.7 | -15.8 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | 0.1 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.4% | | 0.0% |
| Net income | -92.9 | -92.9 | -82.3 | -82.3 | -46.2 | -29.1 | -20.8 | -15.8 |
| Net margin | | -115.7% | | -117.3% | | -229.4% | -129.1% | -188.3% |
| |
| Diluted EPS | ($3.33) | ($3.33) | ($3.36) | ($3.36) | ($2.42) | ($1.64) | ($1.38) | ($1.53) |
| Shares outstanding (diluted) | 27.9 | 27.9 | 24.5 | 24.5 | 19.1 | 17.7 | 15.1 | 10.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|